Literature DB >> 14722026

Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis.

Roland Buettner1, Iris Ottinger, Jürgen Schölmerich, L Cornelius Bollheimer.   

Abstract

Recent in vivo studies have demonstrated a strong negative correlation between liver triglyceride content and hepatic insulin sensitivity, but a causal relationship remains to be established. We therefore have examined parameters of direct hepatic insulin action on isolated steatotic livers from high-fat (HF)-fed rats compared with standard chow (SC)-fed controls. Direct hepatic action of insulin was assayed in Wistar rats after 6 wk of HF diet by measuring the insulin-induced suppression of epinephrine-induced hepatic glucose output in an isolated liver perfusion system. Insulin-induced activation of glycogen synthase was measured by quantifying the incorporation of radioactive UDP-glucose into glycogen in HF and SC liver lysates. HF diet induced visceral obesity, mild insulin resistance, and hepatic steatosis. Both suppression of epinephrine-induced glycogenolysis and activation of glycogen synthase by insulin were sustained in HF rats; no significant difference from SC controls could be detected. In conclusion, in our model, triglyceride accumulation into the liver was not sufficient to impair direct hepatic insulin action. The data argue for an important role of systemic factors in the regulation of hepatic glucose output and hepatic insulin sensitivity in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722026     DOI: 10.1152/ajpendo.00453.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  14 in total

Review 1.  Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Metin Basaranoglu; Serra Kayacetin; Nevin Yilmaz; Ertugrul Kayacetin; Orhan Tarcin; Abdullah Sonsuz
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Peroxisome proliferator-activated receptors and hepatitis C virus.

Authors:  M Eslam; M A Khattab; S A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

3.  The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.

Authors:  Fadila Benhamed; Pierre-Damien Denechaud; Maud Lemoine; Céline Robichon; Marthe Moldes; Justine Bertrand-Michel; Vlad Ratziu; Lawrence Serfaty; Chantal Housset; Jacqueline Capeau; Jean Girard; Hervé Guillou; Catherine Postic
Journal:  J Clin Invest       Date:  2012-05-01       Impact factor: 14.808

4.  Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis.

Authors:  Markus Neumeier; Claus Hellerbrand; Erwin Gäbele; Roland Buettner; Cornelius Bollheimer; Johanna Weigert; Andreas Schäffler; Thomas S Weiss; Monika Lichtenauer; Jurgen Schölmerich; Christa Buechler
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

5.  Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis.

Authors:  Junji Yokozawa; Takashi Sasaki; Kumiko Ohwada; Yayoi Sasaki; Jun-Itsu Ito; Takafumi Saito; Sumio Kawata
Journal:  J Gastroenterol       Date:  2009-04-14       Impact factor: 7.527

Review 6.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.

Authors:  Catherine Postic; Jean Girard
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

7.  Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent.

Authors:  Laura H Tetri; Metin Basaranoglu; Elizabeth M Brunt; Lisa M Yerian; Brent A Neuschwander-Tetri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

8.  Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease.

Authors:  Irene P Tzanetakou; Ilias P Doulamis; Laskarina-Maria Korou; George Agrogiannis; Ioannis S Vlachos; Alkisti Pantopoulou; Dimitri P Mikhailidis; Efstratios Patsouris; Ioannis Vlachos; Despina N Perrea
Journal:  Open Cardiovasc Med J       Date:  2012-08-10

9.  Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis.

Authors:  Roberto Conti; Edoardo Mannucci; Pompeo Pessotto; Emanuela Tassoni; Paolo Carminati; Fabio Giannessi; Arduino Arduini
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

10.  Larix laricina, an Antidiabetic Alternative Treatment from the Cree of Northern Quebec Pharmacopoeia, Decreases Glycemia and Improves Insulin Sensitivity In Vivo.

Authors:  Despina Harbilas; Diane Vallerand; Antoine Brault; Ammar Saleem; John T Arnason; Lina Musallam; Pierre S Haddad
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.